Skip to main content

Drug Interactions between dezocine and DiHydro-GP

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

dezocine dihydrocodeine

Applies to: dezocine and DiHydro-GP (dihydrocodeine / guaifenesin / pseudoephedrine)

GENERALLY AVOID: Concomitant use of opioids with other central nervous system (CNS) depressants including mixed agonist-antagonist or partial agonist opioids may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased. On the other hand, mixed agonist-antagonist or partial agonist opioids can reduce the pharmacologic effects of other opioid agonists. Reduced efficacy or withdrawal symptoms may occur in patients maintained on their opioid regimen following the addition of a mixed agonist-antagonist or partial agonist opioid.

MANAGEMENT: The use of opioids in conjunction with other CNS depressants including mixed agonist-antagonist or partial agonist opioids should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary (e.g., when initiating a switch from one opioid to the other), the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, and patients should be closely monitored for signs and symptoms of CNS and respiratory depression. Additional caution is advisable when a mixed agonist-antagonist or partial agonist opioid is added to an existing opioid regimen, as there may be an increased risk of withdrawal symptoms (e.g., restlessness, insomnia, sweating, lacrimation, or rhinorrhea) following initiation of the mixed agonist-antagonist or partial agonist opioid. A dosage adjustment for one or both drugs may be required.

References (11)
  1. Moldenhauer CC, Roach GW, Finlayson DC, et al. (1985) "Nalbuphine antagonism of ventilatory depression following high-dose fentanyl anesthesia." Anesthesiology, 62, p. 647-50
  2. Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
  3. Strain EC, Preston KL, Liebson IA, Bigelow GE (1993) "Precipitated withdrawal by pentazocine in methadone-maintained volunteers." J Pharmacol Exp Ther, 267, p. 624-34
  4. (2001) "Product Information. Nubain (nalbuphine)." Endo Laboratories LLC
  5. (2001) "Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc
  6. (2001) "Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals
  7. (2001) "Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company
  8. (2001) "Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals
  9. (2002) "Product Information. Suboxone (buprenorphine-naloxone)." Reckitt and Colman Pharmaceuticals Inc
  10. (2002) "Product Information. Subutex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc
  11. (2010) "Product Information. Butrans (buprenorphine)." Purdue Pharma LP

Drug and food/lifestyle interactions

Major

dezocine food/lifestyle

Applies to: dezocine

GENERALLY AVOID: Alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics. Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills. In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur. In addition, alcohol may affect opioid release from sustained-release formulations.

MANAGEMENT: Patients should not consume alcoholic beverages or use drug products that contain alcohol during treatment with opioid analgesics. Any history of alcohol or illicit drug use should be considered when prescribing an opioid analgesic, and therapy initiated at a lower dosage if necessary. Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.

References (9)
  1. (2024) "Product Information. Oxymorphone Hydrochloride (oxyMORphone)." Aurolife Pharma LLC
  2. (2024) "Product Information. Levorphanol Tartrate (levorphanol)." Virtus Pharmaceuticals LLC
  3. (2025) "Product Information. Nalbuphine Hydrochloride (nalbuphine)." Hospira Inc
  4. (2024) "Product Information. Remifentanil Hydrochloride (remifentanil)." Fresenius Kabi USA, LLC
  5. (2022) "Product Information. Remifentanil (remifentanil)." Wockhardt UK Ltd
  6. (2024) "Product Information. Cyclizine-Dipipanone (cyclizine-dipipanone)." Advanz Pharma
  7. Cherrier MM, Shen DD, Shireman L, et al. (2021) "Elevated customary alcohol consumption attenuates opioid effects." Pharmacol Biochem Behav, 4, p. 1-27
  8. (2024) "Product Information. Oxymorphone Hydrochloride ER (oxyMORphone)." Amneal Pharmaceuticals LLC
  9. (2025) "Product Information. Dihydrocodeine (dihydrocodeine)." Ennogen Healthcare International Ltd
Major

dihydrocodeine food/lifestyle

Applies to: DiHydro-GP (dihydrocodeine / guaifenesin / pseudoephedrine)

GENERALLY AVOID: Alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics. Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills. In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur. In addition, alcohol may affect opioid release from sustained-release formulations.

MANAGEMENT: Patients should not consume alcoholic beverages or use drug products that contain alcohol during treatment with opioid analgesics. Any history of alcohol or illicit drug use should be considered when prescribing an opioid analgesic, and therapy initiated at a lower dosage if necessary. Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.

References (9)
  1. (2024) "Product Information. Oxymorphone Hydrochloride (oxyMORphone)." Aurolife Pharma LLC
  2. (2024) "Product Information. Levorphanol Tartrate (levorphanol)." Virtus Pharmaceuticals LLC
  3. (2025) "Product Information. Nalbuphine Hydrochloride (nalbuphine)." Hospira Inc
  4. (2024) "Product Information. Remifentanil Hydrochloride (remifentanil)." Fresenius Kabi USA, LLC
  5. (2022) "Product Information. Remifentanil (remifentanil)." Wockhardt UK Ltd
  6. (2024) "Product Information. Cyclizine-Dipipanone (cyclizine-dipipanone)." Advanz Pharma
  7. Cherrier MM, Shen DD, Shireman L, et al. (2021) "Elevated customary alcohol consumption attenuates opioid effects." Pharmacol Biochem Behav, 4, p. 1-27
  8. (2024) "Product Information. Oxymorphone Hydrochloride ER (oxyMORphone)." Amneal Pharmaceuticals LLC
  9. (2025) "Product Information. Dihydrocodeine (dihydrocodeine)." Ennogen Healthcare International Ltd
Moderate

pseudoephedrine food/lifestyle

Applies to: DiHydro-GP (dihydrocodeine / guaifenesin / pseudoephedrine)

MONITOR: Coadministration of two or more sympathomimetic agents may increase the risk of adverse effects such as nervousness, irritability, and increased heart rate. Central nervous system (CNS) stimulants, particularly amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.

MANAGEMENT: Caution is advised if two or more sympathomimetic agents are coadministered. Pulse and blood pressure should be closely monitored.

References (7)
  1. Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr (1979) "Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients." Psychiatry Res, 1, p. 45-52
  2. Cavanaugh JH, Griffith JD, Oates JA (1970) "Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man." Clin Pharmacol Ther, 11, p. 656
  3. (2001) "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc
  4. (2001) "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals
  5. (2001) "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals
  6. (2001) "Product Information. Focalin (dexmethylphenidate)." Mikart Inc
  7. (2002) "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer